SM
AVDL

Sabby Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Sabby Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-12,100
Closed -$148K – 302
2015
Q4 		$148K Buy
+12,100
New +$189K 0.01% 291

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Sabby Management's AVDL Position: Q1 2016 in Review

Sabby Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 12,100 shares — an estimated $148K sold.

Sabby Management first reported a position in AVDL in Q4 2015 and held it in 1 quarter. The position peaked at $148K in Q4 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

  • Sabby Management reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Sabby Management sold 12,100 Avadel Pharmaceuticals shares in Q1 2016, an estimated $148K.
  • Sabby Management first reported a position in Avadel Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Sabby Management's Avadel Pharmaceuticals position peaked at $148K in Q4 2015.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.